Entyvio

(vedolizumab)

Uses, side effects, dosage information & price range

Takeda Pharma A/S

About this medicine

Ulcerative colitis Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF?) antagonist. Crohns disease Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohns disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF?) antagonist. Pouchitis Entyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

TepezzaComposition: teprotumumabAmgen Europe B.V.

Price on RequestView Details →

Key Information

Salt / Composition

vedolizumab